The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease -- despite an FDA advisory committee concluding last year ...

The FDA approved the drug despite a "no" vote from its advisory committee, whose members felt the medicine did little to ...

WASHINGTON - Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated ...

At its November meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted against Biogen's controversial Alzheimer's drug aducanumab (Aduhelm), ...

CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...

The likelihood of Biogen becoming a potential takeover target may have risen with new CEO Michel Vounatsos and the launch of potential blockbuster drug Spinraza. Sanofi might want to explore an ...

Biogen’s main business for now is multiple sclerosis. But sales could be hurt soon by a new drug from Roche. In the last months, there have been two failures in Alzheimer’s disease trials from Eli ...

(Reuters) - Biogen Inc revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed ...